[Click eStock] Huons, Performance Growth Centered on Health Functional Foods Rather Than Prescription Drugs
[Asia Economy Reporter Lee Seon-ae] Shin Young Securities maintained a 'Buy' investment opinion and a target price of 77,000 KRW for Huons.
According to Shin Young Securities on the 16th, despite the stagnation in the prescription drug business during the COVID-19 pandemic in 2020, Huons was able to achieve continuous performance growth through the performance growth and profitability turnaround of its beauty and well-being business health functional food subsidiaries (Huons Natural, Huons Nature). The consolidated sales in 2020 increased by 11.4% year-on-year to 406.7 billion KRW, and operating profit increased by 11.7% to 54.1 billion KRW. While prescription drugs remained at the previous year's level of 184.3 billion KRW, the beauty and well-being business, centered on health functional foods, increased by 23.3%, and consignment manufacturing increased by 16.3%.
This performance growth is expected to continue.
In November last year, Huons issued 50 billion KRW worth of convertible bonds (CB) and is currently promoting the construction of a dedicated eye drop factory in Plant 2, following the expansion of the eye drop production line in 2019. The introduction of a state-of-the-art production line and the transfer of the complex production line from Plant 1 to Plant 2 aim to operate the factory more efficiently (with a capacity of 480 million units). The factory is scheduled to be completed in January 2022, receive KGMP certification, and start operation in 2023.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- Even After the 'Tax,' High Profits Remain... Korea Emerges as a Premium Market [ChwiYakGukga]②
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Researcher Lee Myung-sun of Shin Young Securities explained, "Huons is advancing further as an ophthalmology-specialized company by establishing Plant 2 and focusing on the development of eye drop pipelines such as nano-composite eye drops (HUC2-007) and Thymosin β4 (HUB1-023)," adding, "We maintain the target price due to continuous performance growth and smooth pipeline development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.